Tax-cover sale by Twist Bioscience (NASDAQ: TWST) president

Rhea-AI Filing Summary

Twist Bioscience Corp’s President and COO Patrick John Finn reported an open-market sale of 2,321 shares of Common Stock at $60.761 per share. According to the footnote, these shares were sold solely to cover tax withholding triggered by vesting of Restricted Stock Units under the company’s equity plans and were not discretionary trades. After this transaction, he directly holds 281,808 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 2,321 shares ($141,026)

Net Sell 1 txn

Insider Finn Patrick John

Role President and COO

Sold 2,321 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,321	$60.761	$141K

Holdings After Transaction: Common Stock — 281,808 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,321 shares Sale price: $60.761 per share Post-transaction holdings: 281,808 shares

3 metrics

Shares sold 2,321 shares Open-market sale on 2026-04-23

Sale price $60.761 per share Tax-related sale to cover withholding

Post-transaction holdings 281,808 shares Direct ownership after sale

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"funded by a "sell to cover" transaction and do not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"Issuer's election under its equity incentive plans to require"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		2,321	D	$60.761	281,808	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Twist Bioscience (TWST) report for Patrick John Finn?

Twist Bioscience reported that President and COO Patrick John Finn sold 2,321 shares of common stock at $60.761 per share. The filing states the sale was to cover tax withholding from vesting Restricted Stock Units, rather than a discretionary trade.

Why did Patrick John Finn’s Twist Bioscience shares get sold in this Form 4?

The shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The company’s equity incentive plans require a mandated “sell to cover” transaction for these taxes, meaning the sale was automatic, not an elective market decision.

How many Twist Bioscience (TWST) shares does Patrick John Finn hold after this transaction?

After the reported transaction, Patrick John Finn directly holds 281,808 shares of Twist Bioscience common stock. This figure reflects his post-sale position and shows that the tax-related sale affected only a portion of his overall direct holdings.

At what price were Patrick John Finn’s Twist Bioscience shares sold in the Form 4?

The 2,321 shares of Twist Bioscience common stock were sold at an average price of $60.761 per share. This price comes directly from the Form 4 disclosure describing the transaction as an open-market sale used to satisfy tax withholding obligations.

Does the Form 4 indicate that Patrick John Finn’s Twist Bioscience sale was discretionary?

No. The footnote explains the sale was mandated under Twist Bioscience’s equity incentive plans as a “sell to cover” for tax withholding on RSU vesting. It specifically states these transactions do not represent discretionary trades by the reporting person.